

RECEIVED
CENTRAL FAX CENTER

OCT 06 2009

Attorney's Docket No.: AVI-000CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ivarie, et al.
Patent No. : 7,521,591
Issue Date : April 21, 2009
Serial No. : 10/696,671
Filed : October 28, 2003
Title : TRANSGENIC CHICKENS THAT LAY EGGS CONTAINING EXOGENOUS PROTEINS

Art Unit : 1633
Examiner : Kaushal, Sumesh

Docket No.: AVI-000CON

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop, Amendments, Honorable Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted to the U.S. Patent and Trademark Office on or before:

Date Oct 6, 2009
Signature [Signature]
Name Hyke Yasland

RESPONSE TO APPLICATION FOR PATENT TERM ADJUSTMENT UNDER
37 C.F.R. § 1.705(d)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In a Decision on Application for Patent Term Adjustment Under 37 C.F.R. § 1.705(d) ("Decision") dated August 6, 2009, the United States Patent and Trademark Office ("Office") dismissed Patentees' Application For Patent Term Adjustment (PTA) Under 37 C.F.R. § 1.705(d) for the above patent. The Office agreed with Patentees' request that the patent be accorded 116 days of "B Delay;" however, the Office did not follow Patentees' request to apply the rule set forth in Wyeth v. Dudas, 580 F. Supp. 2d 138 (D.D.C. 2008) with respect to the

Applicant : Invarje, et al.
Patent No. : 7,521,591
Issued : April 21, 2009
Serial No. : 10/696,671
Filed : October 28, 2003
Page : 2 of 4

Attorney's Docket No.: AVI-000CON

calculation of "overlap" of "A Delay" and "B Delay." The legal issue concerning the calculation of such "overlap" is identical to the legal issue decided by Wyeth. Following the Wyeth precedent would result in a total PTA calculation of 217 days, for the reasons detailed in Patentees' Application for PTA filed on May 15, 2009.

The Office acknowledged that Patentee requested recalculation of PTA according to the rule set forth in Wyeth. See decision at pages 2-3. However, that acknowledgement was the sole mention of the Wyeth case in the entire Decision. Most of the Decision puts forth the Office's support for a legal argument that had been considered and rejected by the court in Wyeth. The Office's arguments appear to be presented anew in the Decision as though the Wyeth case has no relevance to the present PTA calculation.

The statute governing PTA instructs a patentee dissatisfied with a determination made by the Director to pursue a civil action against the Director in the United States District Court for the District of Columbia. 35 USC §154(b)(4)(A). The statute makes clear that the District Court for the District of Columbia is the sole court with jurisdiction to hear such PTA challenges. It was under this statutory provision that Wyeth brought its action against the Director and prevailed on the exact same legal issue that is in contention for the present patent. Still, and despite the previous adverse ruling on this legal issue, the Office in the present Decision has ignored the clear ruling of the only district court with authority to consider PTA challenges.

As the identical legal issue of the present PTA challenge has already been decided by the only district court with authority to consider PTA challenges, Patentees submit that the Office should either follow the law as interpreted by that court or stay a final decision in this matter until the ongoing appeal of the Wyeth decision has been decided by an appellate court. Subsequent to the Wyeth decision, numerous patentees have filed suits in the District Court for the District of Columbia challenging PTA calculations based on the same legal issue presented in Wyeth. Because the District Court for the District of Columbia has already decided the issue and the Office has appealed that decision to the Federal Circuit, the Office and the plaintiffs have requested stays of most or all of those litigations pending the outcome of that appeal. Fairness dictates that the Office act in a consistent manner during the present administrative process.

Applicant : Invaric, et al.
Patent No. : 7,521,591
Issued : April 21, 2009
Serial No. : 10/696,671
Filed : October 28, 2003
Page : 3 of 4

Attorney's Docket No.: AVI-000CON

Given its current legal posture, it would be fundamentally unfair for the Office to render a final ruling on this issue when its interpretation of the statute and rules have been rejected by the court and it is currently seeking to have that adverse ruling reversed on appeal.

The Decision states that "Patentees' interpretation of the period of overlap has been considered, but found inconsistent with the Office's interpretation of the overlap provision, [of 35 USC §154(b)(2)(A)]." Decision at page 3. However, as noted above, the district court with sole jurisdiction to hear PTA challenges has squarely rejected the Office's interpretation of this statutory provision. "While deference is to be given to an agency's interpretation of the statute it administers [citations omitted], it is the courts that have the final word on matters of statutory interpretation." Ithaca College v. NLRB, 623 F.2d 224, 228 (2d Cir. 1980) (citing *inter alia* Marbury v. Madison, 5 U.S. (1 Cranch) 137, 177, 2 L.Ed. 60 (1803)). By comparison to the Office's apparent disregard for the precedent of the District Court for the District of Columbia in calculating PTA for the present patent, the National Labor Relations Board has been admonished for its practice of refusing to follow unfavorable decisions from the courts in instances where it was likely that a case at issue would come up for review before the very court with which the Board disagrees.

Of course, we do not expect the Board or any other litigant to rejoice in all the opinions of this Court. When it disagrees in a particular case, it should seek review in the Supreme Court. During the interim before it has sought review or while review is still pending, it would be reasonable for the Board to stay its proceedings in another case that arguably falls within the precedent of the first one. However, the Board cannot, as it did here, choose to ignore the decision as if it had no force or effect. Absent reversal, that decision is the law which the Board must follow. The Board cites no contrary authority except its own consistent practice of refusing to follow the law of the circuit unless it coincides with the Board's views. This is intolerable if the rule of law is to prevail.

Id. Similarly, absent a reversal by the Federal Circuit or the Supreme Court, the Office cannot act in a manner that ignores the Wyeth decision as if it had no force or effect.

Patentees request that the Office follow the legal authority of Wyeth and increase total PTA for the present patent to 217 days (for the same reasons detailed in the Application for PTA filed on May 15, 2009). If the Office is unwilling to follow the ruling in Wyeth while the appeal


Applicant : Invarie, et al.
Patent No. : 7,521,591
Issued : April 21, 2009
Serial No. : 10/696,671
Filed : October 28, 2003
Page : 4 of 4

Attorney's Docket No.: AVI-000CON

of that decision is ongoing, then it should at a minimum follow the rationale it has put forth recently in PTA litigations pending before the District Court for the District of Columbia and stay a final decision on this matter until the Wyeth appeal has been completed. It is the courts, and not the Office, that must have the final word on this matter of statutory interpretation.

No fee is believed due. However, if any fee is due, please charge it to Deposit Account No. 501729, referencing Attorney Docket Number AVI-000CON.

Respectfully submitted



Kyle Yesland, 706-227-1170, ext 233
Attorney for Applicants
Reg. No. 45,526
Synageva BioPharma Corp.
Legal Department
111 Riverbend Road
Athens, GA 30605